Study on Obesity, Insulin Resistance, and Long COVID

This study is looking into how obesity and insulin resistance (when your body doesn't respond well to insulin, a hormone that helps control blood sugar) might be connected to Long COVID (PASC: Persistent SARS-CoV-2). Researchers want to see if fat tissue plays a role in Long COVID by causing ongoing inflammation or by holding onto the SARS-CoV-2 virus. You might be able to join if you are between 18 and 80 years old, have a BMI (Body Mass Index) of 25 or higher, and are not pregnant. The study involves procedures like an Adipose Tissue Biopsy (removing a small amount of fat tissue) and a Steady State Plasma Glucose (SSPG) Test (an insulin sensitivity test). The goal is to understand if obesity and insulin resistance are risk factors for Long COVID and to find new ways to treat it.

Study design
This is an interventional study with a planned enrollment of 55 participants. The phase of the study is not specified, and its current status is unclear.
What's involved
You would undergo an Adipose Tissue Biopsy (a small fat removal) every three months for one year. You would also have a 5-6 hour Steady State Plasma Glucose (SSPG) Test, which requires a 12-hour fast.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes like the Triglyceride/HDL-cholesterol ratio, viral RNA in fat tissue, and inflammatory response rate at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05833217

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Recruiting
NAAges 18–80InterventionalPrevention
Stanford University
~55 participants
Updated 2024-12-04 on ClinicalTrials.gov
What's tested:Adipose Tissue BiopsySteady State Plasma Glucose (SSPG) Test

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Triglyceride/HDL-cholesterol ratio
Measured over 2 years
+3 more outcomes measured
Long COVID
Insulin Resistance
Insulin Sensitivity
2 sites across 1 states
California2
  • Tracey McLaughlin, MD · PRINCIPAL_INVESTIGATOR · Stanford School of Medicine

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 18 to 80
BMI ≥ 25 kg/m2
not currently pregnant

Exclusion

pregnancy
prior liposuction
recent change in weight (\> 2 kg in one month)
bleeding disorders
anticoagulant use
major organ disease
diabetes
history of liposuction
bariatric surgery
eating disorders
psychiatric disorders
pregnancy or lactation
recent change in weight (over the past 12 weeks),
use of weight loss medication or oral steroids
hematocrit \< 33%
fasting glucose \>= 126 mg/dL
blood pressure \>160/100 mmHg
  • Triglyceride/HDL-cholesterol ratio2 years

    Investigate the relationship between insulin resistance, as described by triglyceride/HDL-cholesterol ratio, and incident PASC (long COVID).

  • Concentration of Viral RNA in Adipose Tissue2 years

    Investigate the expression of viral RNA in adipose tissue in response to COVID-19 infection. Compare adipose tissue transcripts such as known MODY transcription factors measured by PCR between COVID-19 infected participants and healthy controls.

  • Rate of Inflammatory Response2 years

    Investigate inflammatory response to PPARgamma agonist (drug) and other compounds tested in vitro in human fat cells. Compare plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay between participants identified as Insulin Sensitive (IS) and Insulin Resistant (IR) using the 2-stage Steady State Plasma Glucose test.

  • Rate of Inflammatory Gene Expression in Adipose Tissue2 years

    Investigate the expression of inflammatory genes in adipose tissue in response to COVID-19 infection. Compare adipose tissue transcripts such as defensin chemokine receptors and platelet activation factors measured by PCR between COVID-19 infected participants and healthy controls.